Cloned (Comment) | Organism |
---|---|
gene ERG3, DNA and amino acid sequence determination and analysis | Candida albicans |
gene ERG3, DNA and amino acid sequence determination and analysis, transcriptome analysis | Candida parapsilosis |
Protein Variants | Comment | Organism |
---|---|---|
G111R | naturally occurring mutation, the mutant is obtained from a patient with prosthetic valve endocarditis, the mutant shows reduction in sterol desaturase activity and resistance to azole and echinocandin antifungals, replacement of both mutant alleles in the resistant isolate with the susceptible isolate's allele restores wild-type susceptibility to all azoles and echinocandins tested. | Candida parapsilosis |
additional information | an ERG3 deletion construct for Candida albicans is generated by amplifying an ApaI-XhoI containing fragment consisting of flanking regions upstream from positions -350 to +39 relative to the start codon of Candida albicans ERG3 using primers CaERG3A-F and CaERG3B-R, as well as a NotI-SacIIcontaining fragment consisting of flanking regions from positions +997 to +1677 downstream of the start codon using primers CaERG3C-F and CaERG3D-R. These upstream and downstream fragments are cloned upstream and downstream, respectively, of the SAT1-flipper cassette in plasmid pSFS2, resulting in pCaERG3M1 | Candida albicans |
additional information | an ERG3 deletion construct for Candida parapsilosis is generated by amplifying an ApaI-XhoI-containing fragment consisting of flanking regions upstream from positions -280 to +51 relative to the start codon of Candida parapsilosis ERG3 using primers ERG3-A and ERG3-B, as well as a NotI-SacII-containing fragment consisting of downstream flanking regions from positions +1047 to +1868 using primers ERG3-C and ERG3-D. These upstream and downstream fragments of ERG3 are cloned upstream and downstream, respectively, of the SAT1-flipper cassette in plasmid pSFS2 to result in plasmid p77ERG3 | Candida parapsilosis |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
posaconazole | - |
Candida albicans |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Candida albicans | Q59VG6 | - |
- |
Candida parapsilosis | A0A1L2BH72 | - |
- |
Candida parapsilosis CDC317 | A0A1L2BH72 | - |
- |
Synonyms | Comment | Organism |
---|---|---|
C-5 sterol desaturase | - |
Candida parapsilosis |
C-5 sterol desaturase | - |
Candida albicans |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
35 | - |
assay at | Candida parapsilosis |
35 | - |
assay at | Candida albicans |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
7 | - |
assay at | Candida parapsilosis |
7 | - |
assay at | Candida albicans |
General Information | Comment | Organism |
---|---|---|
malfunction | a mechanism of antifungal resistance in this organism affecting susceptibility to azole and echinocandin antifungals is found in a clinical isolate obtained from a patient with prosthetic valve endocarditis. Transcriptome analysis indicates differential expression of several genes in the resistant isolate, including upregulation of ergosterol biosynthesis pathway genes ERG2, ERG5, ERG6, ERG11, ERG24, ERG25, and UPC2. Whole-genome sequencing reveals that the resistant isolate possesses an ERG3 mutation resulting in a G111R amino acid substitution. Sterol profiles indicate a reduction in sterol desaturase activity as a result of this mutation. Replacement of both mutant alleles in the resistant isolate with the susceptible isolate's allele restores wild-type susceptibility to all azoles and echinocandins tested | Candida parapsilosis |
additional information | sterol composition of wild-type isolate and ERG3 mutants, overview | Candida parapsilosis |
additional information | sterol composition of wild-type isolate and ERG3 mutants, overview | Candida albicans |